re: apart from the potential CAR-T applications, SGMO's programs should be confined primarily to aut | SGMO Message Board Posts

Sangamo BioSciences Inc.

  SGMO website

SGMO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  84615 of 84803  at  1/11/2017 2:49:06 PM  by

Watsonncrick

The following message was updated on 1/11/2017 3:52:03 PM.

re: apart from the potential CAR-T applications, SGMO's programs should be confined primarily to autologous HSCs (e.g., the BCL11a enhancer program) so #1 about improved conditioning regimens to "make room" for gene edited HSCs is worth reading

  
  
  
  
 I've posted previously about reviews that summarize "state of the art" approaches to hematopoietic stem cell (HSC) gene editing mentioning that less toxic conditioning regimens are desirable and emerging.  
 
Note the statement in #1, that for Bluebird's trials "their main toxicities, so far have been due to conditioning regimens", so obviously any process of depleting existing HSCs w/ less toxicity will be welcome, & should be helpful to incorporate into SGMO's HSC-related gene editing trials, if possible.
 
As you'll recall, these condition regimens are designed to deplete existing HSCs in bone marrow to "make room" for the engraftment of newly transplanted gene edited, HSCs.
 
 
 
 
 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 6     Views: 268
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2016 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.

Loading...